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ABSTRACT  
New therapies for advanced adrenocortical carcinoma (ACC) are urgently needed, as the majority 
of the patients experience a rapid and inexorable progression despite surgery and adjuvant 
mitotane. In vitro data suggest that somatostatin receptors (SSTR) and mTOR pathway might 
represent reasonable targets for novel therapies, being involved in functionality and growth of 
adrenocortical cancer (ACC) cells. However, in vitro analysis of combination treatments targeting 
both mTOR and SSTR as compared to mitotane are poorly explored in ACC. This study aimed to 
investigate in vitro the effects on cell growth of pasireotide, everolimus and mitotane, alone or 
combined, in the two ACC cell lines H295R and SW13 (mitotane sensitive and resistant, 
respectively). Moreover, the tissue expression of mTOR pathway molecules and SSTR (types 1-5) 
was assessed in 58 ACC. In both cell lines, only everolimus induced a significant inhibition of cell 
growth. Conversely the combinations among mitotane, pasireotide and everolimus produced 
antagonistic effects on mitotane-induced growth inhibition on H295R cell line. An heterogeneous 
profile of mTOR-related molecules and SSTR expression was observed in ACC samples, being the 
mTOR pathway found activated in approximately 30% of cases. In conclusion, our data suggest 
caution in designing combinations of mitotane with other drugs potentially active in ACC, such as 
mTOR inhibitors or somatostatin analogs.  
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Adrenocortical carcinoma (ACC) is a rare malignancy, which has an aggressive biological behavior 
and a dismal prognosis, with a 5-year survival limited to 16-44% [1, 2]. Surgical resection is the 
only curative therapy, and is often followed by adjuvant mitotane to increase the chance of cure 
[3, 4]. However, high recurrence rates are observed even in early-stage patients. Therapeutic 
options for disseminated disease are associated with adverse effects and do not clearly improve 
survival [2]. Mitotane remains the only FDA-approved drug, with reported response rates (based 
on uncontrolled trials and small case series) of 21%, when used as a single agent [2]. As for 
cytotoxic chemotherapy, the effect is relatively limited. Recently, in a phase III randomized 
prospective trial the regimen etoposide, doxorubicin and cisplatin combined with mitotane 
determined a longer progression-free survival with a 23.2% response rate, but clear-cut benefit on 
overall survival were not observed [5]. As the majority of the patients experience a rapid and 
inexorable progression, new therapies for advanced ACC are urgently needed. The most common 
molecular event in ACC is the overexpression of insulin-like growth factor receptor 2 (IGFR-2), 
detected in up to 90% of tumours [6, 7, 8, 9]. In a recent phase III study on advanced or metastatic 
ACC patients, [10] linsitinib, an inhibitor of both IGF-1R and insulin receptor, did not increase 
overall survival. However, the IGF-1R pathway is reported to synergize with several other signaling 
pathways, including mammalian target of rapamycin (mTOR) pathway. In this regard, a partial 
response with prolonged survival was reported [11] in a phase I clinical trial combining the anti-
IGF-1R antibody cixutumumab with the mTOR inhibitor temsirolimus. Conversely, the 
administration of everolimus to advanced ACC patients in combination or previously treated with 
mitotane resulted in limited clinical improvement [12]. In ACC cell lines, an antiproliferative role 
has been documented with the mTOR inhibitors sirolimus [13], temsirolimus [14] and everolimus 
[15, 16].  Among other drug targetable molecules documented in adrenocortical tumors, there are 
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somatostatin receptors (SSTR) [17, 18, 19]. The multi-ligand somatostatin analog pasireotide was 
demonstrated to inhibit hormonal secretion in ACC cell lines without effects on cell proliferation 
[19]. Moreover, pasireotide has been considered an effective treatment of Cushing’s disease since 
it inhibits ACTH and corticosterone release both in vitro and in vivo [20, 21, 22]. In vitro 
experiments on neuroendocrine tumor cell lines indicated that somatostatin analogs enhanced 
the antiproliferative action of rapamycin probably acting in synergy on the PI3K/AKT/mTOR 
signaling pathway [23, 24]. Finally, several clinical trials showed an additional therapeutic value in 
combining a somatostatin analog with everolimus in advanced neuroendocrine tumors [25, 26].  
To the best of our knowledge, in ACC cell lines, two reports only addressed the issue of associated 
treatments, combining sirolimus and mitotane [13] and everolimus and sorafenib [16], showing an 
additive and a synergic antiproliferative effect, respectively. 
Therefore, the aim of the present study was to further explore potential combination treatment 
strategies through the evaluation of the reciprocal effects of everolimus, pasireotide and mitotane 
in two ACC cell lines (the mitotane sensitive H295R and the mitotane resistant SW13). The 
expression levels of potential targets of mTOR inhibitors and somatostatin analogs in a series of 
resected ACC were also assessed. 
 
MATERIAL AND METHODS 
Cell culture and chemical reagents - NCI-H295R and SW-13 ACC cell lines were supplied from the 
American Type Culture Collection (LGC Standards s.r.l., Sesto San Giovanni, Milan, Italy). The 
H295R cells were cultured in a 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's F-12 
Nutrient mixture (DMEM/F12) (Sigma-Aldrich, St. Louis, USA) supplemented with 2 mmol/L L-
glutamine, penicillin (25 units/mL), and streptomycin (25 mg/mL, all from Sigma-Aldrich) and 2.5% 
of Nu-Serum (BD Biosciences, San Jose, CA) and enriched with 1% di ITS+Premix (BD Biosciences, 
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San Jose, CA). The SW-13 cells were cultured in DMEM (Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (Biowest, Nuaillè, France) and 2 mmol/L L-glutamine, penicillin (25 units/mL), 
and streptomycin (25 mg/mL, all from Sigma-Aldrich). o,p’DDD, (Sigma-Aldrich, St. Louis, USA) and 
everolimus (Sequoia Research, Pangbourne, UK) were dissolved in 100% methanol (Sigma-Aldrich, 
St. Louis, USA). Pasireotide was a generous gift from Novartis and was dissolved in sterile distilled 
water. 
 
Treatment and cell viability assay - SW13 and H295R cell lines were seeded into 96-well plates in 
triplicates and treated with pasireotide and mitotane or everolimus, either alone or in 
combination, for 72h (from 10 nM to 103 nM for each drug). The combination between different 
drugs was performed at fixed concentration ratios (1:1). After incubation, Cell Proliferation 
Reagent WST-1 (Roche Applied Science, Germany) was added to each well in order to measure cell 
proliferation, following the supplied protocol. Cell viability ratios were calculated using the 
sigmoid inhibition model (GraphPad PRISM 5). Drug interaction between pasireotide, mitotane 
and everolimus was assessed using the combination index (CI), where CI < 1, CI = 1, and CI > 1 
indicate synergistic, additive and antagonistic effects, respectively. CI was determined by IC50 of 
each drugs and the combination with drugs [27]. 
 
SSTR and mTOR mRNA expression evaluation with Real Time PCR - H295R and SW-13 cell lines 
were cultured into six-well plates and treated with 250nM of everolimus, mitotane and 
pasireotide, alone or in combination for 72 hours. Total RNA was extracted using Qiazol Reagent 
(Qiagen, West Sussex, UK). Complementary DNA was generated using M-MLVT RT (200U/µl) 
(Invitrogen, Invitrogen Corporation, USA) and oligodT primers (500µl/ml) (Invitrogen, Invitrogen 
Corporation, USA) from 1µg of total RNA according to standard protocols. Relative cDNA 
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quantification for somatostatin receptors or mTOR and an internal reference gene (β-actin) was 
done in duplicate using a fluorescence-based real-time detection method (ABI PRISM7900 
Sequence Detection System - TaqMan; Applied Biosystems, Foster City, CA, USA) using pre-
designed primers and probes (SSTR types from Life Technologies and mTOR and β-actin from 
Roche Applied Sciences). To analyze target gene expression in treated cells, mRNA levels were 
normalized to the housekeeping gene β-actin, then ΔΔCt calculation was performed and the 
corresponding values were expressed as 2-ΔΔCt. 
 
Tissue collection – 58 adrenocortical carcinomas diagnosed according to the Weiss Score [28] 
(including six myxoid and nine oncocytic subtypes) were retrieved from the pathology files of the 
University of Turin at San Luigi Hospital. The nine oncocytic tumors were also reclassified 
according to the Lin-Weiss-Bisceglia scheme [29], and four of them proved to be of uncertain 
malignant potential according to this more appropriate score for oncocytic neoplasms. These 
cases were incorporated into two tissue microarrays, assembled as previously described [30]. The 
majority of these patients were treated at our Institution, which serves as a referral center for 
adrenocortical carcinoma therapy in Italy. Clinical and pathological data of these patients are 
summarized in Table 1. The study received ethical approval from the local Review Board of our 
Institution. 
 
Immunohistochemistry – Five μm thick paraffin sections serial to those used for conventional 
hematoxylin and eosin staining were obtained for immunohistochemical reactions from the TMAs.  
The following antibodies were employed: p-mTOR (Ser 2448, rabbit monoclonal, clone 49F9, 
diluted 1/100; Cell Signaling, Beverly, MA, USA), p-p70S6K (Thr 389, mouse monoclonal, clone 1A5, 
diluted 1/400; Cell Signaling, Beverly, MA, USA), p-Akt (Ser473, rabbit polyclonal, diluted 1/40; Cell 
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Signaling, Beverly, MA, USA), p-4EBP1 (Thr 37/46, rabbit polyclonal, diluted 1/300; Cell Signaling), 
p-Raptor (Ser792, rabbit polyclonal, diluted 1/100; Cell Signaling), SSTR1 (mouse monoclonal, 
clone N35B 15E9, diluted 1/1000, supplied by Novartis Pharma), SSTR2 (rabbit monoclonal, clone 
UMB1, diluted 1/1000; Epitomics, Burlingame, CA, USA), SSTR3 (mouse monoclonal, clone N37A 
QS5G8A12, diluted 1/700, supplied by Novartis Pharma), SSTR4 (mouse monoclonal, clone N55 
19E7-F7, diluted 1/600, supplied by Novartis Pharma), SSTR5 (mouse monoclonal, clone N38 
17D10 2/38, diluted 1/500, supplied by Novartis Pharma).   
 
Staining interpretation and scoring system – All slides were analyzed by two of us (ED, MV) and 
all samples were considered adequate for all antibodies in the presence of at least two suitable 
cores after sectioning and staining procedures. Staining was assessed for all but one antibodies, 
using a binary scoring system based on the evaluation of cytoplasmic/membrane staining:  score 
0= no staining, score 1= positive staining.  
 
Statistical analysis - Reciprocal correlations among the different antibodies expression levels were 
made using a two-tailed Spearman’s test. Staining patterns for each antibody tested were 
compared to clinical and pathological characteristics using Chi-square or Student’s t tests, as 
appropriate. The prognostic impact of the different antibody expression levels was tested in 
univariate overall survival analysis using the Kaplan–Meier product limit estimate of survival 
distribution and the Log Rank test. All parameters with a significant impact on survival at 
univariate analysis were included in multivariate analysis using the Cox proportional hazard model.  
Statistical significance was set at p<0.05. All tests were performed using GraphPad Prism version 





Everolimus, but not pasireotide, is active as cytotoxic agent in adrenocortical cancer cells 
Everolimus induced a dose-dependent decrease of cell viability in the two adrenal cancer cell lines 
(Figure 1), more intense in SW-13 with IC50 values of 0.52 nM (standard error ± 0.55) (at 72 h of 
treatment) rather than in H295R cells with IC50 values of 3.23 nM (standard error ± 1.58) (at 72 h 
of treatment). Conversely, pasireotide had no evident effect on cell viability when both ACC cell 
lines were treated using increasing doses of the drug (IC50 values of 16.45±2.56 μM in SW13 cells 
and 5.16±0.85 in H295R cells). 
 
Different effects of pasireotide, everolimus and mitotane combinations in mitotane-sensitive 
and insensitive adrenocortical cancer cells 
We confirmed the previously demonstrated [31] drug-responsiveness profiles of the two cell lines, 
as, after a 72 hour treatment, mitotane produced poor cytotoxic effects in SW13 cell lines, while 
the viability of H295R cells was impaired. In the association of mitotane with everolimus, mitotane 
blocked everolimus activity in both SW-13 and H295R cell lines, independently of their 
responsiveness to mitotane, with a combination index (CI=1.38±0.38 and 4.56±3.13) indicating an 
antagonistic effect of the two drugs (Figure 1A and 1D). The association of mitotane and 
pasireotide determined opposing effects in the two cell lines. In fact, in mitotane insensitive SW-
13 cells, the combination index (CI=0.22±0.15) indicated a synergistic anti-proliferative effect of 
mitotane and pasireotide. Conversely, the same combination produced an antagonistic effect on 
cell growth (CI=3.11±2.13) in mitotane-sensitive H295R cells (Figure 1C and 1F). Similarly, the 
combination of pasireotide and everolimus determined a synergistic cytotoxic effect (CI=0.69±0.25) 
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in SW-13 cells and an antagonistic effect (CI=2.55±1.60) on cell growth in H295R cells  (Figure 1B 
and 1E). 
 
Combined treatments of pasireotide, everolimus and mitotane differentially modulate SSTRs 
and of mTOR gene expression in adrenocortical cancer cells 
At basal level, H295R and SW13 cell lines showed a very low expression of all SSTRs (data not 
shown).  Pasireotide administration, alone or in combination with mitotane or everolimus, 
induced a modulation of gene expression of all SSTRs in H295R cells. An up-regulation of all SSTR 
types was found with the association pasireotide/mitotane, but a two-fold decrease of only SSTR2 
levels was observed with the pasireotide/everolimus treatment. Conversely, SSTR gene expression 
levels did not vary in SW13 lines treated with the same combinations (Figure 2).  Concerning 
mTOR gene expression, the treatment with everolimus, alone and in combination with mitotane 
or pasireotide, did not determine any change of the expression levels. 
 
mTOR pathway molecules and SSTRs are heterogeneously expressed in ACC tissues and 
correlate with clinical and pathological parameters and survival 
Overall, using immunohistochemistry, p-mTOR expression was observed in 18 (32%) cases, with a 
moderate or strong cytoplasmic reactivity (Figure 3, A-E), while the other downstream molecules 
were variably expressed in the cytoplasm of tumor cells (range 29-59%). SSTRs were variably 
expressed in 29% (SSTR2) up to 83% (SSTR4) of cases, with a membrane or cytoplasmic reactivity 
(Figure 3, F-L) (Table 2). Among the mTOR pathway molecules, a positive correlation was found 
only between p-p70S6K and p-4EBP (r= 0.4664, p=0.0002), while among SSTRs, only SSTR1 and 
SSTR3 were reciprocally correlated (r= 0.3132, p=0.0177). p-AKT was positive in younger patients 
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(Chi-square test, p=0.044), conversely SSTR1 and SSTR3 were positive in the older patient group 
(Chi-square test, p=0.029 and p=0.007 for SSTR1 and SSTR3, respectively).  
p-mTOR and SSTR3 expression was significantly different in oncocytic ACC (Chi-square test, 
p=0.025 and p=0.0016, respectively), being negative in all cases, as compared to conventional and 
myxoid variants. p-mTOR was also negative in tumors with high Weiss Score (Chi-square test, 
p=0.025), whereas SSTR3 was negative in tumors with low Weiss Score (Chi-square test, p=0.01). 
Finally, SSTR1 was associated to cases having a high mitotic activity (Chi-square test, p=0.007). 
Univariate analysis showed that high mitotic rate (p=0.0132), high Ki-67 proliferation index 
(p=0.0001) and SSTR5 expression (p=0.0173) were associated with shorter overall survival (Table 
3). At multivariate analysis, Ki-67 and SSTR5 expression remained significant independent 




In this study, we demonstrated that pasireotide and everolimus interact differently when 
combined with mitotane or with each other, determining variable effects on viability of ACC cell 
lines. Moreover, SSTR5 expression was found to be significantly associated with a poor prognosis 
in a cohort of resected ACCs. 
ACC cell lines. As the most frequent molecular abnormality in ACC affects the IGF axis, which 
ultimately leads to an activation of the mTOR pathway, several studies investigated the 
effectiveness of mTOR inhibitors in ACC cell lines. Consistently, an antiproliferative effect was 
observed when used as a single agent [14] or in combination, either with a tyrosine kinase 
inhibitor (everolimus plus sorafenib) [16] or mitotane (temsirolimus plus mitotane). This paper 
aimed to investigate in vitro the potential synergistic effects of the mTOR inhibitor everolimus 
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and/or the somatostatin analog pasireotide with mitotane. We found that everolimus induced a 
significant inhibition of cell growth in both mitotane sensitive and resistant cell lines, but its effect 
was reduced when administrated in combination with mitotane. Conversely, the association of 
pasireotide with mitotane or everolimus determined opposite effects in H295R and SW-13 cell 
lines. We previously demonstrated that in H295R cells, the association of effective drugs, namely 
gemcitabine and mitotane, caused a reduction of citotoxic activity of these compounds on cell 
viability [31]. Similarly, in the present study, all combinations of drugs produced antagonistic 
effects on the inhibition of growth in such cell line. Interestingly, in mitotane resistant SW13 cells, 
the combination of pasireotide with mitotane, both determining poor effects on cell viability when 
administrated as single agents, was synergistic, though not effective enough to generate a 
significant growth inhibition. Conversely, the combination of mitotane and everolimus in the same 
mitotane resistant cell line determined an antagonistic effect, despite everolimus efficacy when 
administered alone. Anyway, in both cell lines, the synergy or antagonism caused by drug 
combinations was unable to induce relevant changes on cell viability compared to single 
treatments. In H295R cells, the insufficient or reduced effects of pasireotide, alone or in 
combination with mitotane and everolimus, went along with an up-regulation of all somatostatin 
receptor subtypes, an event that did not occur in SW13 cells. These findings indicate that H295R 
and SW13 cells had different response profiles to the combined or single drug treatments, and 
that their mechanism(s) of action involved different pathways. Although our in vitro data are 
opposite to those reported by De Martino et al. [13] with temsirolimus and mitotane on the same 
cell lines, they support the clinical experience of Fraenkel et al. [12], who reported the failure of 
everolimus to induce any therapeutic benefit in advanced ACC patients, who were heavily 
pretreated with multiple lines of systemic agents, including mitotane. CYP3A4, which metabolizes 
everolimus, is strongly induced by mitotane, and this effect persists up to one year after 
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interruption of mitotane treatment [32, 33]. Therefore, interactions between mTOR and mitotane 
are common and could be expected [33]. The drug interaction induced by the combination of 
targeted molecular agents with adjuvant mitotane can potentially result in reduced therapeutic 
efficacy of these compounds in the treatment of ACC. Therefore the therapeutic efficacy of 
everolimus should be evaluated prior to treatment with mitotane and monitoring of the blood 
levels of these drugs will be essential in assuring their putative effect.  
 
ACC tissue. Searching for other explanations of the treatment failure and to verify a potential 
differential protein expression in ACC according to clinico-pathological features, we investigated 
the expression of SSTR and of phosphorylated molecules of the mTOR pathway by means of 
immunohistochemistry in 58 ACC cases. Our data are consistent with the previously described 
variability of SSTR expression in ACC samples [17, 19]. We found that the absence of SSTR3 was 
correlated with the oncocytic variant, which is the least aggressive variant of ACC, and with low 
Weiss Score tumors. Interestingly, Mariniello et al. [19] reported the absence of SSTR3 in normal 
adrenal and in the majority of adrenocortical adenomas. Moreover, we observed a higher 
expression of SSTR1 in cases with high mitotic rate and a relationship of SSTR5 expression with a 
worse outcome. Although an antisecretive effect of pasireotide on ACC cells has been reported in 
vitro, we did not identify any correlation with the functionality of the tumor. Concerning mTOR 
pathway molecules, they were variably expressed, but unlike De Martino et al. [34], we could not 
confirm a reciprocal correlation between the expression levels of the phosphorylated form of 
mTOR and either S6K or 4EBP. A specific signature predicting response to mTOR inhibition has not 
been identified, yet. De Martino et al.  [34] reported that at least a subgroup of the tumors with 
more aggressive pathological phenotype (high Weiss Score), showed weak staining of p-S6K and p-
4EBP, indicating that a subset of less differentiated ACCs could be less dependent on the 
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activation of the mTOR pathway. The identification of the phosphorylated form of mTOR, S6K and 
4EBP, cannot be employed as an established surrogate marker of mTOR inhibitor efficacy. 
However, the immunohistochemical overexpression of SSTR and mTOR pathway molecules can 
suggest the activation of these targets, at least in a subset of patients.  
In conclusion, all combinations among mitotane, pasireotide and everolimus produced an 
antagonistic effects on mitotane-induced growth inhibition in the mitotane sensitive H295R cell 
line. This suggests a prudent clinical approach in designing therapeutic combinations of mitotane 
with other drugs potentially active in ACC, such as mTOR inhibitors or somatostatin analogs. An 
heterogeneous expression profile of mTOR-related molecules and SSTR(s) was observed in ACC 
samples, thus confirming that only a subset of patients with ACC might be more sensitive than 
other and benefit from treatment with these drugs. Further studies are required to better refine 
the potential biomarkers predictive of response to mitotane, mTOR inhibitors or somatostatin 
analog  treatment(s) in adrecortical cancer. 
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Figure 1.  Cell viability after single or combined pasireotide, mitotane and everolimus treatment. 
Cytotoxic response to pasireotide, mitotane and everolimus and their combination in H295R and 
SW13 cell lines. Data result from three different experiments (±SD, n=3) and are expressed as 
ratios of proliferating cells, as compared to basal conditions.  
Figure 2. SSTR subtype gene expression after single or combined pasireotide, mitotane and 
everolimus treatment. SSTRs gene expression analysis in H295R and SW13 cell lines under 
different conditions. Data are expressed as fold changes (2-ΔΔCt).  A fold change >2 was considered 
significant. 
Figure 3.  Representative examples of ACCs immunostained for p-mTOR (A), p-70S6K (B), p-AKT (C), 
p-4EBP (D), p-RAPTOR (E), SSTR1 (F), SSTR2 (G), SSTR3 (H), SSTR4 (I), SSTR5 (L). (A-L: 
immunoperoxidase, original magnification 400X). 
 
 
 
